The New England Journal of Medicine May 15, 2014

Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection

Nezam Afdhal, Stefan Zeuzem, Paul Kwo, et al.

Bottom Line

In previously untreated patients with HCV genotype 1 infection, an all-oral, once-daily regimen of ledipasvir and sofosbuvir achieved a near-perfect sustained virologic cure rate, with no added benefit from extending treatment to 24 weeks or adding ribavirin.

Key Findings

1. Sustained virologic response at 12 weeks (SVR12) was achieved in 99% of patients receiving 12 weeks of ledipasvir-sofosbuvir alone (95% CI, 96 to 100) and 97% of those receiving 12 weeks of ledipasvir-sofosbuvir plus ribavirin (95% CI, 94 to 99).

2. Extending the duration of therapy to 24 weeks provided no additional virologic benefit, yielding SVR12 rates of 98% for ledipasvir-sofosbuvir alone and 99% for ledipasvir-sofosbuvir plus ribavirin.

3. Efficacy was consistently high across all patient subgroups; notably, the presence of compensated cirrhosis (16% of the cohort) or specific HCV genotype 1 subtype (1a vs. 1b) did not compromise the SVR12 rates.

4. The 12-week ribavirin-free regimen was highly tolerable; zero patients in the 12-week ledipasvir-sofosbuvir monotherapy arm discontinued treatment due to adverse events.

5. The most common adverse events overall were mild and included fatigue, headache, insomnia, and nausea, which were more prominent in the ribavirin-containing arms.

Study Design

Design

RCT

Open-Label

Sample

865

Patients

Duration

12 wk post-treatment

Median

Setting

Multicenter

Population Previously untreated adult patients with chronic HCV genotype 1 infection, including up to 20% with compensated cirrhosis

Intervention Fixed-dose combination tablet of ledipasvir and sofosbuvir once daily for 12 or 24 weeks

Comparator Fixed-dose combination of ledipasvir and sofosbuvir plus ribavirin for 12 or 24 weeks

Outcome Sustained virologic response at 12 weeks after the end of therapy (SVR12)

Study Limitations

• The open-label design of the trial introduces potential bias in the reporting of subjective adverse events, such as fatigue and headache.

• The study cohort predominantly consisted of white patients, limiting the evaluation of efficacy and safety in broader racial demographics, though no signal of reduced efficacy was seen in black patients (12% of the cohort).

• Patients with decompensated liver disease, severe renal impairment, or HIV coinfection were excluded, limiting the immediate generalizability to these more medically complex populations.

Clinical Significance

The ION-1 trial was a landmark study that revolutionized the treatment of hepatitis C. By demonstrating that a single daily pill of ledipasvir-sofosbuvir (Harvoni) could cure 99% of treatment-naive genotype 1 patients in just 12 weeks without the need for ribavirin, it firmly established an incredibly safe, highly efficacious, and universally tolerated standard of care. This allowed clinicians to confidently treat HCV even in patients with compensated cirrhosis, effectively ending the era of interferon-based therapy.

Historical Context

For decades, the standard treatment for HCV genotype 1 was a grueling 24- to 48-week regimen of pegylated interferon and ribavirin, which yielded suboptimal cure rates (~50%) and severe, often dose-limiting side effects. While the introduction of first-generation protease inhibitors (telaprevir, boceprevir) improved response rates, they still required an interferon backbone and added significant toxicity. The advent of direct-acting antivirals (DAAs), specifically the combination of sofosbuvir (a nucleotide analog NS5B polymerase inhibitor) and ledipasvir (an NS5A inhibitor), offered the first widely applicable, interferon-free, all-oral cure. Published alongside ION-2 (evaluating previously treated patients) and ION-3 (evaluating 8-week therapy), the ION-1 trial heralded the modern era of HCV eradication.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

Ledipasvir and sofosbuvir target different steps in the hepatitis C virus (HCV) life cycle. What are their specific molecular targets, and why is combination therapy conceptually superior to monotherapy in treating RNA viruses like HCV?

Key Response

Ledipasvir is an NS5A inhibitor, and sofosbuvir is a nucleotide analog inhibitor of the NS5B RNA-dependent RNA polymerase. Because HCV is an RNA virus lacking proofreading capability, it has a high mutation rate. Using two drugs with distinct, non-overlapping mechanisms prevents the rapid emergence of resistant viral variants, a fundamental concept in antiviral therapy.

Resident

Based on the ION-1 trial results, how does the omission of ribavirin and the shortening of therapy to 12 weeks change the contraindication profile and side-effect management for a newly diagnosed, treatment-naive patient with HCV genotype 1?

Key Response

Historically, ribavirin caused severe hemolytic anemia and is highly teratogenic, while interferon caused severe psychiatric and systemic side effects. The ION-1 trial showed ribavirin was unnecessary with ledipasvir/sofosbuvir, meaning this highly effective, well-tolerated regimen could now be safely prescribed to patients with baseline anemia, childbearing potential, or psychiatric comorbidities who were previously ineligible for HCV treatment.

Fellow

The ION-1 trial included a subset of patients with compensated cirrhosis. How did the sustained virologic response (SVR) rates for compensated cirrhotics compare to non-cirrhotics in this trial, and how did subsequent data modify the treatment approach for genotype 1 patients with decompensated cirrhosis?

Key Response

In ION-1, patients with compensated cirrhosis achieved >95% SVR, suggesting 12 weeks without ribavirin was highly effective. However, fellows must recognize that for decompensated cirrhosis (Child-Pugh B or C), subsequent trials (like SOLAR-1) demonstrated that adding ribavirin or extending therapy to 24 weeks is often necessary to maximize SVR and prevent relapse, highlighting the limits of standard 12-week regimens in advanced disease.

Attending

The ION-1 trial demonstrated near-100% cure rates, effectively transforming HCV into an easily curable infectious disease. From a public health and health-systems perspective, what are the primary remaining barriers to HCV eradication in the modern era, given that drug efficacy is no longer the limiting factor?

Key Response

With efficacy proven, the attending-level focus shifts to implementation and systemic barriers. These include inadequate screening, loss to follow-up in the care cascade, high drug costs leading to prior authorization restrictions by insurers, and the challenge of reinfection in high-risk populations (e.g., persons who inject drugs), which require comprehensive harm reduction strategies alongside medical therapy.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The ION-1 trial utilized an open-label design rather than a double-blind, placebo-controlled approach. Given the primary endpoint of SVR12, what are the methodological justifications for an open-label design here, and what potential biases does it introduce regarding the trial's secondary endpoints?

Key Response

Because SVR12 is a strictly objective laboratory measure (undetectable HCV RNA), an open-label design does not significantly threaten the internal validity of the primary efficacy endpoint. However, it introduces significant reporting and observer bias for subjective secondary endpoints like adverse events (e.g., fatigue, headache), especially when comparing arms with and without notoriously toxic drugs like ribavirin.

Journal Editor

As a peer reviewer evaluating the ION-1 manuscript, how would you critique the statistical powering and sample size allocation for the subgroup of patients with cirrhosis, and does this limitation affect the strength of the conclusion that 12 weeks without ribavirin is universally sufficient for all treatment-naive patients?

Key Response

Only about 16% (136 of 865) of the trial population had cirrhosis. A rigorous reviewer would flag that the trial is likely underpowered to definitively rule out a small but clinically meaningful benefit of ribavirin or 24 weeks of therapy specifically in this cirrhotic subgroup, which historically represents the most difficult-to-cure demographic.

Guideline Committee

How did the findings of the ION-1 trial influence the AASLD/IDSA HCV guidelines regarding the preferred regimen for treatment-naive HCV Genotype 1, and what specific evidence grade would be assigned to the recommendation against routine ribavirin use in non-cirrhotic patients?

Key Response

ION-1 provided Class I, Level A evidence (randomized, well-powered trial) that revolutionized AASLD/IDSA guidelines, establishing ledipasvir/sofosbuvir for 12 weeks as a first-line, preferred regimen for treatment-naive GT1 non-cirrhotics. It simultaneously provided the evidence base to strongly recommend against the inclusion of ribavirin in this specific population, radically simplifying the standard of care.

Clinical Landscape

Noteworthy Related Trials

2014

ION-2 Trial

n = 440 · NEJM

Tested

Ledipasvir and Sofosbuvir with or without ribavirin for 12 or 24 weeks

Population

Treatment-experienced patients with HCV genotype 1 infection

Comparator

Comparison between 12-week and 24-week durations, with and without ribavirin

Endpoint

Sustained virologic response at 12 weeks (SVR12)

Key result: The SVR12 rates ranged from 94% to 99% across all groups, demonstrating high efficacy even in patients with cirrhosis who previously failed therapy.

2014

ION-3 Trial

n = 647 · NEJM

Tested

Ledipasvir and Sofosbuvir for 8 weeks (with or without ribavirin)

Population

Treatment-naive patients with HCV genotype 1 infection without cirrhosis

Comparator

Ledipasvir and Sofosbuvir for 12 weeks

Endpoint

Sustained virologic response at 12 weeks (SVR12)

Key result: An 8-week course of Ledipasvir and Sofosbuvir was noninferior to a 12-week course, achieving an SVR12 rate of 94%.

2014

SAPPHIRE-I Trial

n = 631 · NEJM

Tested

Ombitasvir/paritaprevir/ritonavir plus dasabuvir and ribavirin

Population

Treatment-naive adults with HCV genotype 1 infection without cirrhosis

Comparator

Placebo

Endpoint

Sustained virologic response at 12 weeks (SVR12)

Key result: The multi-targeted DAA regimen achieved an overall SVR12 rate of 96.2% with low rates of discontinuation due to adverse events.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis